[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488717":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":107,"collaborators":19,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":19,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":19,"enrollmentInfo":118,"targetDuration":19,"studyType":121,"phases":122,"briefSummary":125,"conditions":126,"keywords":135,"overallStatus":33,"whyStopped":19,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":150},{"fullName":5,"class":6},"CRISPR Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CTX112","EXPERIMENTAL","Administered by IV infusion following lymphodepleting chemotherapy.",[13],"Biological: CTX112",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Melanie Allen, M.Sc.","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":19,"email":29},"Clinical Trials","CONTACT","+1 (877) 214-4634","MedicalAffairs@crisprtx.com",[31,45,55,65,75,87,97],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":19},"University of Kansas","RECRUITING","Westwood","Kansas","66205","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-94.6169,39.04056,{"lat":43,"lon":42},{"facility":46,"status":33,"city":47,"state":48,"zip":49,"country":37,"countryCode":38,"cosmosGeoPoint":50,"geoPoint":54,"contacts":19},"Washington University","St Louis","Missouri","63110",{"type":40,"coordinates":51},[52,53],-90.19789,38.62727,{"lat":53,"lon":52},{"facility":56,"status":33,"city":57,"state":58,"zip":59,"country":37,"countryCode":38,"cosmosGeoPoint":60,"geoPoint":64,"contacts":19},"SCRI","San Antonio","Texas","78229",{"type":40,"coordinates":61},[62,63],-98.49363,29.42412,{"lat":63,"lon":62},{"facility":66,"status":33,"city":67,"state":68,"zip":69,"country":37,"countryCode":38,"cosmosGeoPoint":70,"geoPoint":74,"contacts":19},"University of Utah","Salt Lake City","Utah","84112",{"type":40,"coordinates":71},[72,73],-111.89105,40.76078,{"lat":73,"lon":72},{"facility":76,"status":33,"city":77,"state":78,"zip":79,"country":80,"countryCode":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":19},"Royal Prince Alfred","Camperdown","New South Wales","2050","Australia","AU",{"type":40,"coordinates":83},[84,85],151.17642,-33.88965,{"lat":85,"lon":84},{"facility":88,"status":33,"city":89,"state":90,"zip":91,"country":80,"countryCode":81,"cosmosGeoPoint":92,"geoPoint":96,"contacts":19},"Alfred Health","Melbourne","Victoria","3004",{"type":40,"coordinates":93},[94,95],144.96332,-37.814,{"lat":95,"lon":94},{"facility":98,"status":33,"city":99,"state":100,"zip":101,"country":80,"countryCode":81,"cosmosGeoPoint":102,"geoPoint":106,"contacts":19},"Sir Charles Gairdner Hospital","Nedlands","Western Australia","6009",{"type":40,"coordinates":103},[104,105],115.8073,-31.98184,{"lat":105,"lon":104},{"type":108,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100488717","phase-1-a-safety-and-efficacy-study-evaluating-ctx112-in-subjects-with-relapsed-or-refractory-b-cell-malignancies-100488717",false,"NCT05643742","A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies","A Phase 1\u002F2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies","Key Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Refractory or relapsed B cell malignancy.\n3. Eastern Cooperative Oncology Group performance status 0 or 1.\n4. Adequate renal, liver, cardiac and pulmonary organ function.\n5. Female subjects of childbearing potential and male subjects must agree to use acceptable method(s) of contraception from enrollment through at least 12 months after CTX112 infusion.\n\nKey Exclusion Criteria:\n\n1. Prior allogeneic hematopoietic stem cell transplant (HSCT).\n2. Active or history of central nervous system (CNS) involvement by malignancy.\n3. History of a seizure disorder, cerebrovascular ischemia\u002Fhemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.\n4. Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV anti-infectives.\n5. Active HIV, hepatitis B virus or hepatitis C virus infection.\n6. Previous or concurrent malignancy in the last 3 years (with the exception of non-melanoma skin cancer and other cancers deemed by the investigator and medical monitor to be of low likelihood for recurrence).\n7. Concurrent systemic treatment with an anticancer biologic (e.g., monoclonal antibody) within 30 days prior to CTX112 infusion or with a nonbiological anticancer drug within 14 days prior to CTX112 infusion.\n8. Primary immunodeficiency disorder or active autoimmune disease requiring steroids and\u002For other immunosuppressive therapy.\n9. Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":119,"type":120},120,"ESTIMATED","INTERVENTIONAL",[123,124],"PHASE1","PHASE2","This is an open-label, multicenter, Phase 1\u002F2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.",[127,128,129,130,131,132,133,134],"B-cell Lymphoma","Non-Hodgkin Lymphoma","B-cell Malignancy","Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Large B-cell Lymphoma",[136,137,138,139],"CAR T","Non-Hodgkin Lymphoma (NHL)","Lymphoma","Allogeneic","2025-11-13",{"date":142,"type":143},"2025-11-14","ACTUAL",{"date":145,"type":143},"2023-03-10",{"date":147,"type":120},"2030-02",{"name":149,"class":6},"CRISPR Therapeutics AG",7]